Aurora M. Fontainhas

Array ( [id] => 18093145 [patent_doc_number] => 20220411486 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => Humanized Antibodies That Recognize Alpha-Synuclein [patent_app_type] => utility [patent_app_number] => 17/730074 [patent_app_country] => US [patent_app_date] => 2022-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12938 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17730074 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19916199 [patent_doc_number] => 12291552 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-06 [patent_title] => Chimeric protein in the treatment of amyloidosis [patent_app_type] => utility [patent_app_number] => 17/729534 [patent_app_country] => US [patent_app_date] => 2022-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 12 [patent_no_of_words] => 15989 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17729534 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19738331 [patent_doc_number] => 12215149 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-04 [patent_title] => Anti-MS4A6A antibodies and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/722624 [patent_app_country] => US [patent_app_date] => 2022-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 7 [patent_no_of_words] => 45597 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 200 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17722624 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19172504 [patent_doc_number] => 20240158478 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => SARS-CoV-2 Antibodies and Fragments, Therapeutic Uses, Diagnostic Uses, and Compositions Related Thereto [patent_app_type] => utility [patent_app_number] => 18/282409 [patent_app_country] => US [patent_app_date] => 2022-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12706 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18282409 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18145746 [patent_doc_number] => 20230019602 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-19 [patent_title] => METHODS FOR TREATMENT OF MOTOR NEURON DISEASES [patent_app_type] => utility [patent_app_number] => 17/688717 [patent_app_country] => US [patent_app_date] => 2022-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14983 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17688717 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17881260 [patent_doc_number] => 20220296737 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-22 [patent_title] => IMMUNOPET AND IMMUNOSPECT IMAGING TO IDENTIFY CYTOTOXIC T CELL ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/686230 [patent_app_country] => US [patent_app_date] => 2022-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9675 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17686230 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19187854 [patent_doc_number] => 20240166767 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-23 [patent_title] => HUMANIZED ANTIBODIES AGAINST IRHOM2 [patent_app_type] => utility [patent_app_number] => 18/279715 [patent_app_country] => US [patent_app_date] => 2022-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27273 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18279715 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18567121 [patent_doc_number] => 20230257450 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-17 [patent_title] => antiRPS4Y1 mAb [patent_app_type] => utility [patent_app_number] => 17/673912 [patent_app_country] => US [patent_app_date] => 2022-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3695 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17673912 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19210737 [patent_doc_number] => 11999785 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-04 [patent_title] => Binding molecule specific for Lrig-1 protein and use thereof [patent_app_type] => utility [patent_app_number] => 17/672208 [patent_app_country] => US [patent_app_date] => 2022-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 13 [patent_no_of_words] => 11243 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17672208 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17911279 [patent_doc_number] => 20220313674 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-06 [patent_title] => PSILOCYBIN COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 17/669845 [patent_app_country] => US [patent_app_date] => 2022-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5453 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17669845 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19961605 [patent_doc_number] => 12331089 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-17 [patent_title] => Channelrhodopsins for optical control of cells [patent_app_type] => utility [patent_app_number] => 17/668766 [patent_app_country] => US [patent_app_date] => 2022-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 28 [patent_no_of_words] => 16913 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17668766 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17627245 [patent_doc_number] => 20220162260 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-26 [patent_title] => USE OF LOW PH AND DEXTRAN SULFATE DURING HARVEST TREATMENT FOR PROTEIN PURIFICATION [patent_app_type] => utility [patent_app_number] => 17/666891 [patent_app_country] => US [patent_app_date] => 2022-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8690 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17666891 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17627287 [patent_doc_number] => 20220162302 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-26 [patent_title] => ANTIBODIES USEFUL IN CANCER DIAGNOSIS [patent_app_type] => utility [patent_app_number] => 17/666122 [patent_app_country] => US [patent_app_date] => 2022-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25590 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17666122 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17595356 [patent_doc_number] => 20220144929 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => ANTI-SEMA3A ANTIBODIES AND THEIR USES FOR TREATING EYE OR OCULAR DISEASES [patent_app_type] => utility [patent_app_number] => 17/583245 [patent_app_country] => US [patent_app_date] => 2022-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19984 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17583245 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19052241 [patent_doc_number] => 20240094210 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => METHOD FOR TREATING SOLUBLE GPC3-CONTAINING SPECIMEN IN SOLUBLE GPC3 IMMUNOASSAY [patent_app_type] => utility [patent_app_number] => 18/261207 [patent_app_country] => US [patent_app_date] => 2022-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7937 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18261207 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18987795 [patent_doc_number] => 20240059764 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => ANTIGEN-BINDING PROTEIN TARGETING STAPHYLOCOCCUS AUREUS a-HEMOLYSIS AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 18/271804 [patent_app_country] => US [patent_app_date] => 2022-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16281 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -53 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18271804 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18727108 [patent_doc_number] => 20230341389 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => COMPOSITIONS AND METHODS FOR DIAGNOSING PRIMARY BILIARY CIRRHOSIS [patent_app_type] => utility [patent_app_number] => 18/007700 [patent_app_country] => US [patent_app_date] => 2022-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15708 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18007700 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20207311 [patent_doc_number] => 20250277031 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-09-04 [patent_title] => ANTIBODY SPECIFICALLY BINDING TO CD47 AND ANTIGEN-BINDING FRAGMENT THEREOF [patent_app_type] => utility [patent_app_number] => 18/260725 [patent_app_country] => US [patent_app_date] => 2022-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14677 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18260725 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17929783 [patent_doc_number] => 20220324908 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-13 [patent_title] => ADVANTAGEOUS SALTS OF MU-OPIATE RECEPTOR PEPTIDES [patent_app_type] => utility [patent_app_number] => 17/554421 [patent_app_country] => US [patent_app_date] => 2021-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8292 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17554421 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17627278 [patent_doc_number] => 20220162293 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-26 [patent_title] => EPITOPES IN THE RNA RECOGNITION MOTIF 1 (RRM1) OF TDP-43 AND MISFOLDING-SELECTIVE ANTIBODIES THERETO [patent_app_type] => utility [patent_app_number] => 17/541812 [patent_app_country] => US [patent_app_date] => 2021-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30914 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17541812 [rel_patent_id] =>[rel_patent_doc_number] =>)